Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide- stimulated rat primary astrocytes

Soon Young Lee, Hee Jin Kim, Woo Jong Lee, So Hyun Joo, Se Jin Jeon, Ji Woon Kim, Hee Sun Kim, Seol Heui Han, Jongmin Lee, Seung Hwa Park, Jae Hoon Cheong, Won-Ki Kim, Kwang Ho Ko, Chan Young Shin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We investigated the effect of the cAMP system on lipopolysaccharide (LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat primary astrocytes. Co-treatment with a cAMP analog, dibutyryl-cAMP (db-cAMP), or the cAMP elevating beta-adrenergic agonist, isoproterenol, concentration-dependently inhibited LPS-induced MMP-9 activity. In contrast, db-cAMP concentration-dependently increased tPA activity in both basal and LPS-stimulated rat primary astrocytes. To confirm the effect of cAMP on MMP-9 and tPA activity, we treated LPS-stimulated astrocytes with cAMP phosphodiesterase inhibitors, IBMX or rolipram, and they exhibited similar effects to db-cAMP, namely decreasing MMP-9 activity and increasing tPA activity. RT-PCR analysis of MMP-9 mRNA expression and MMP-9 promoter luciferase reporter assays revealed transcriptional upregulation by LPS stimulation and downregulation by db-cAMP. In contrast, the level of tPA mRNA expression was increased both by LPS and by cAMP treatment. Consistent with RT-PCR analysis, tPA promoter reporter assays showed increased activity by both LPS and cAMP stimulation. Interestingly, the level of mRNA encoding plasminogen activator inhibitor-1 (PAI-1) was increased by LPS stimulation and decreased back to control level after co-treatment with db-cAMP, suggesting that PAI-1 expression plays a major role in the regulation of tPA activity. To examine PKA involvement in the effects of db-cAMP on MMP-9 and tPA activity, we added the PKA inhibitors, H89 or rp-cAMP, along with db-cAMP, and they inhibited db-cAMP-mediated changes in tPA activity without affecting MMP-9 activity. These data suggest that cAMP differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. The differential regulation of MMP-9 and tPA by the cAMP system may confer more sophisticated regulation of physiological processes, such as extracellular matrix remodeling and cell migration, by activated astrocytes.

Original languageEnglish
Pages (from-to)2324-2334
Number of pages11
JournalNeurochemical Research
Volume33
Issue number11
DOIs
Publication statusPublished - 2008 Nov 1

Fingerprint

Matrix Metalloproteinase 9
Tissue Plasminogen Activator
Astrocytes
Cyclic AMP
Lipopolysaccharides
Rats
Plasminogen Activator Inhibitor 1
Messenger RNA
Assays
Rolipram
Physiological Phenomena
1-Methyl-3-isobutylxanthine
Polymerase Chain Reaction
Adrenergic beta-Agonists
Phosphodiesterase Inhibitors
Level control
Luciferases
Matrix Metalloproteinases
Isoproterenol
Cell Movement

Keywords

  • Isoproterenol
  • PAI-1
  • Post-transcriptional control
  • Promoter activity
  • RT-PCR
  • Zymography

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Biochemistry

Cite this

Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide- stimulated rat primary astrocytes. / Lee, Soon Young; Kim, Hee Jin; Lee, Woo Jong; Joo, So Hyun; Jeon, Se Jin; Kim, Ji Woon; Kim, Hee Sun; Han, Seol Heui; Lee, Jongmin; Park, Seung Hwa; Cheong, Jae Hoon; Kim, Won-Ki; Ko, Kwang Ho; Shin, Chan Young.

In: Neurochemical Research, Vol. 33, No. 11, 01.11.2008, p. 2324-2334.

Research output: Contribution to journalArticle

Lee, Soon Young ; Kim, Hee Jin ; Lee, Woo Jong ; Joo, So Hyun ; Jeon, Se Jin ; Kim, Ji Woon ; Kim, Hee Sun ; Han, Seol Heui ; Lee, Jongmin ; Park, Seung Hwa ; Cheong, Jae Hoon ; Kim, Won-Ki ; Ko, Kwang Ho ; Shin, Chan Young. / Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide- stimulated rat primary astrocytes. In: Neurochemical Research. 2008 ; Vol. 33, No. 11. pp. 2324-2334.
@article{f52c2ee4d16d4e099d1ed3634c89444b,
title = "Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide- stimulated rat primary astrocytes",
abstract = "We investigated the effect of the cAMP system on lipopolysaccharide (LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat primary astrocytes. Co-treatment with a cAMP analog, dibutyryl-cAMP (db-cAMP), or the cAMP elevating beta-adrenergic agonist, isoproterenol, concentration-dependently inhibited LPS-induced MMP-9 activity. In contrast, db-cAMP concentration-dependently increased tPA activity in both basal and LPS-stimulated rat primary astrocytes. To confirm the effect of cAMP on MMP-9 and tPA activity, we treated LPS-stimulated astrocytes with cAMP phosphodiesterase inhibitors, IBMX or rolipram, and they exhibited similar effects to db-cAMP, namely decreasing MMP-9 activity and increasing tPA activity. RT-PCR analysis of MMP-9 mRNA expression and MMP-9 promoter luciferase reporter assays revealed transcriptional upregulation by LPS stimulation and downregulation by db-cAMP. In contrast, the level of tPA mRNA expression was increased both by LPS and by cAMP treatment. Consistent with RT-PCR analysis, tPA promoter reporter assays showed increased activity by both LPS and cAMP stimulation. Interestingly, the level of mRNA encoding plasminogen activator inhibitor-1 (PAI-1) was increased by LPS stimulation and decreased back to control level after co-treatment with db-cAMP, suggesting that PAI-1 expression plays a major role in the regulation of tPA activity. To examine PKA involvement in the effects of db-cAMP on MMP-9 and tPA activity, we added the PKA inhibitors, H89 or rp-cAMP, along with db-cAMP, and they inhibited db-cAMP-mediated changes in tPA activity without affecting MMP-9 activity. These data suggest that cAMP differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. The differential regulation of MMP-9 and tPA by the cAMP system may confer more sophisticated regulation of physiological processes, such as extracellular matrix remodeling and cell migration, by activated astrocytes.",
keywords = "Isoproterenol, PAI-1, Post-transcriptional control, Promoter activity, RT-PCR, Zymography",
author = "Lee, {Soon Young} and Kim, {Hee Jin} and Lee, {Woo Jong} and Joo, {So Hyun} and Jeon, {Se Jin} and Kim, {Ji Woon} and Kim, {Hee Sun} and Han, {Seol Heui} and Jongmin Lee and Park, {Seung Hwa} and Cheong, {Jae Hoon} and Won-Ki Kim and Ko, {Kwang Ho} and Shin, {Chan Young}",
year = "2008",
month = "11",
day = "1",
doi = "10.1007/s11064-008-9737-2",
language = "English",
volume = "33",
pages = "2324--2334",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide- stimulated rat primary astrocytes

AU - Lee, Soon Young

AU - Kim, Hee Jin

AU - Lee, Woo Jong

AU - Joo, So Hyun

AU - Jeon, Se Jin

AU - Kim, Ji Woon

AU - Kim, Hee Sun

AU - Han, Seol Heui

AU - Lee, Jongmin

AU - Park, Seung Hwa

AU - Cheong, Jae Hoon

AU - Kim, Won-Ki

AU - Ko, Kwang Ho

AU - Shin, Chan Young

PY - 2008/11/1

Y1 - 2008/11/1

N2 - We investigated the effect of the cAMP system on lipopolysaccharide (LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat primary astrocytes. Co-treatment with a cAMP analog, dibutyryl-cAMP (db-cAMP), or the cAMP elevating beta-adrenergic agonist, isoproterenol, concentration-dependently inhibited LPS-induced MMP-9 activity. In contrast, db-cAMP concentration-dependently increased tPA activity in both basal and LPS-stimulated rat primary astrocytes. To confirm the effect of cAMP on MMP-9 and tPA activity, we treated LPS-stimulated astrocytes with cAMP phosphodiesterase inhibitors, IBMX or rolipram, and they exhibited similar effects to db-cAMP, namely decreasing MMP-9 activity and increasing tPA activity. RT-PCR analysis of MMP-9 mRNA expression and MMP-9 promoter luciferase reporter assays revealed transcriptional upregulation by LPS stimulation and downregulation by db-cAMP. In contrast, the level of tPA mRNA expression was increased both by LPS and by cAMP treatment. Consistent with RT-PCR analysis, tPA promoter reporter assays showed increased activity by both LPS and cAMP stimulation. Interestingly, the level of mRNA encoding plasminogen activator inhibitor-1 (PAI-1) was increased by LPS stimulation and decreased back to control level after co-treatment with db-cAMP, suggesting that PAI-1 expression plays a major role in the regulation of tPA activity. To examine PKA involvement in the effects of db-cAMP on MMP-9 and tPA activity, we added the PKA inhibitors, H89 or rp-cAMP, along with db-cAMP, and they inhibited db-cAMP-mediated changes in tPA activity without affecting MMP-9 activity. These data suggest that cAMP differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. The differential regulation of MMP-9 and tPA by the cAMP system may confer more sophisticated regulation of physiological processes, such as extracellular matrix remodeling and cell migration, by activated astrocytes.

AB - We investigated the effect of the cAMP system on lipopolysaccharide (LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat primary astrocytes. Co-treatment with a cAMP analog, dibutyryl-cAMP (db-cAMP), or the cAMP elevating beta-adrenergic agonist, isoproterenol, concentration-dependently inhibited LPS-induced MMP-9 activity. In contrast, db-cAMP concentration-dependently increased tPA activity in both basal and LPS-stimulated rat primary astrocytes. To confirm the effect of cAMP on MMP-9 and tPA activity, we treated LPS-stimulated astrocytes with cAMP phosphodiesterase inhibitors, IBMX or rolipram, and they exhibited similar effects to db-cAMP, namely decreasing MMP-9 activity and increasing tPA activity. RT-PCR analysis of MMP-9 mRNA expression and MMP-9 promoter luciferase reporter assays revealed transcriptional upregulation by LPS stimulation and downregulation by db-cAMP. In contrast, the level of tPA mRNA expression was increased both by LPS and by cAMP treatment. Consistent with RT-PCR analysis, tPA promoter reporter assays showed increased activity by both LPS and cAMP stimulation. Interestingly, the level of mRNA encoding plasminogen activator inhibitor-1 (PAI-1) was increased by LPS stimulation and decreased back to control level after co-treatment with db-cAMP, suggesting that PAI-1 expression plays a major role in the regulation of tPA activity. To examine PKA involvement in the effects of db-cAMP on MMP-9 and tPA activity, we added the PKA inhibitors, H89 or rp-cAMP, along with db-cAMP, and they inhibited db-cAMP-mediated changes in tPA activity without affecting MMP-9 activity. These data suggest that cAMP differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. The differential regulation of MMP-9 and tPA by the cAMP system may confer more sophisticated regulation of physiological processes, such as extracellular matrix remodeling and cell migration, by activated astrocytes.

KW - Isoproterenol

KW - PAI-1

KW - Post-transcriptional control

KW - Promoter activity

KW - RT-PCR

KW - Zymography

UR - http://www.scopus.com/inward/record.url?scp=52549111578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52549111578&partnerID=8YFLogxK

U2 - 10.1007/s11064-008-9737-2

DO - 10.1007/s11064-008-9737-2

M3 - Article

VL - 33

SP - 2324

EP - 2334

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 11

ER -